Cargando…
What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment
Polycystic ovary syndrome, the most common gynecological endocrinopathy, is burdened with a state of hyperinsulinemia and insulin resistance in 50–80% of affected women. Wherever the origin of these metabolic abnormalities lies, their pathogenetic role in determining, perpetuating, and worsening the...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236839/ https://www.ncbi.nlm.nih.gov/pubmed/32435760 http://dx.doi.org/10.1177/2633494120908709 |